|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0170 AUD | -5.56% |
|
+41.67% | +13.33% |
| 05-27 | Acrux licenses Lenzetto for Australian market for A$5.4 million | RE |
| 05-27 | Hungary's Richter and Acrux agree to license transdermal estradiol spray for Australia | RE |
| Market Cap | 9.24M 6.46M 5.61M 5.17M 4.84M 9.05M 619M 61.67M 23.87M 298M 24.26M 23.74M 1.04B | P/E Ratio 2024 |
-3.44x | P/E Ratio 2025 | -0.95x |
|---|---|---|---|---|---|
| Enterprise Value | 12.01M 8.4M 7.29M 6.72M 6.3M 11.77M 804M 80.17M 31.04M 388M 31.54M 30.86M 1.35B | EV / Sales 2024 |
4.09x | EV / Sales 2025 | 7.81x |
| Free-Float |
78.27% | Yield 2024 * |
-
| Yield 2025 | - |
| 22-05-22 | Acrux : Application for quotation of securities - ACR | PU |
| 22-04-13 | Acrux : Application for quotation of securities - ACR | PU |
| 22-03-15 | Acrux : Application for quotation of securities - ACR | PU |
| 22-02-24 | Acrux : Updated Board Charter | PU |
| 22-02-24 | Acrux : Application for quotation of securities - ACR | PU |
| 1 day | -5.56% | ||
| 1 week | +41.67% | ||
| Current month | +41.67% | ||
| 1 month | +41.67% | ||
| 3 months | +30.77% | ||
| 6 months | +6.25% | ||
| Current year | +13.33% |
| 1 week | 0.01 | 0.02 | |
| 1 month | 0.01 | 0.02 | |
| Current year | 0.01 | 0.02 | |
| 1 year | 0.01 | 0.02 | |
| 3 years | 0.01 | 0.1 | |
| 5 years | 0.01 | 0.16 | |
| 10 years | 0.01 | 0.84 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Warmbrunn
CEO | Chief Executive Officer | - | 2025-05-31 |
Joanna Johnson
DFI | Director of Finance/CFO | - | 2021-06-20 |
| Chief Tech/Sci/R&D Officer | - | 2015-02-14 |
| Director | Title | Age | Since |
|---|---|---|---|
Geoff Brooke
BRD | Director/Board Member | 70 | 2016-05-31 |
Ross Dobinson
CHM | Chairman | 74 | 2005-12-31 |
Timothy Oldham
BRD | Director/Board Member | - | 2013-09-30 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -5.56% | +41.67% | -22.73% | -67.92% | 6.46M | ||
| +0.76% | +1.44% | +7.14% | +83.45% | 44.96B | ||
| -0.20% | -3.59% | +38.01% | +87.26% | 33.53B | ||
| +0.79% | -0.46% | -7.19% | +45.30% | 11.67B | ||
| -0.10% | +1.42% | +12.84% | +116.57% | 11.62B | ||
| +1.36% | +0.78% | +37.07% | +126.43% | 8.97B | ||
| +2.40% | -0.08% | +17.57% | +42.98% | 6.89B | ||
| -1.12% | -0.56% | +40.12% | -18.60% | 6.55B | ||
| +0.78% | -0.27% | +31.76% | +238.31% | 6.32B | ||
| -0.45% | -2.96% | -39.97% | -6.82% | 5.12B | ||
| Average | -0.19% | +4.21% | +11.46% | +64.70% | 13.56B | |
| Weighted average by Cap. | +0.41% | -1.10% | +17.49% | +83.60% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 5.09M 3.56M 3.09M 2.85M 2.67M 4.99M 341M 33.98M 13.16M 164M 13.37M 13.08M 571M | 1.19M 832K 722K 666K 624K 1.17M 79.7M 7.94M 3.08M 38.42M 3.12M 3.06M 134M |
| Net income | -5.8M -4.06M -3.52M -3.25M -3.04M -5.68M -388M -38.71M -14.99M -187M -15.23M -14.9M -651M | -5.94M -4.16M -3.61M -3.33M -3.12M -5.82M -398M -39.68M -15.36M -192M -15.61M -15.27M -667M |
| Net Debt | 759K 531K 461K 425K 398K 744K 50.84M 5.07M 1.96M 24.5M 1.99M 1.95M 85.2M | 2.77M 1.94M 1.68M 1.55M 1.45M 2.72M 186M 18.5M 7.16M 89.49M 7.28M 7.12M 311M |
Employees
43
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-12 | 0.0170 $ | -5.56% | 2,127,316 |
| 26-06-11 | 0.0180 $ | +12.50% | 3,458,763 |
| 26-06-10 | 0.0160 $ | +33.33% | 5,602,843 |
| 26-06-09 | 0.0120 $ | 0.00% | 719,941 |
| 26-06-05 | 0.0120 $ | 0.00% | 708,933 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- ACR Stock
Select your edition
All financial news and data tailored to specific country editions
















